News | July 23, 2024
Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
The Unit has been issued GMP Certification from ANVISA-Brazil
The approved ANDA is therapeutically equivalent to the reference listed drug product
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Shares and American Depositary Shares of Olink for $26.00 per Share
The academy has secured partnerships with 15 esteemed hospitals
Subscribe To Our Newsletter & Stay Updated
